Isosorbide Mononitrate in Induction of Labour

Labor Fast Clinical Trial

Official title:

Isosorbide Mononitrate and Misoprostol in Induction of Labour

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04482881
• Other study ID #: labour induction
• Status: Not yet recruiting
• Phase: Early Phase 1
• Start date: July 21, 2020
• Est. completion date: September 25, 2020

Study information

• Verified date: July 2020
• Source: Aljazeera Hospital
• Contact: Mahmoud Alalfy
• Phone: 01002611058
• Email: mahmoudalalfy[@]ymail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Induction of labor is defined as the process of artificially initiating uterine contractions, prior to their spontaneous onset, with progressive effacement and dilatation of the cervix and ultimately, the delivery of the baby.

Description:

There are many indications for induction of labor in the obstetric practice, of which prolonged gestational age stands as the most common cause.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 130
• Est. completion date: September 25, 2020
• Est. primary completion date: September 20, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years to 42 Years

Eligibility

Inclusion Criteria:

• Single vertex presentation. 2. Gestational age > 37weeks calculated from last menstrual period or U/S scanning.

Exclusion Criteria:

1. Patients with rupture of membranes.

2. Previous uterine scar.

3. Fetal malpresentation.

4. Multiple pregnancies.

Related Conditions & MeSH terms

• Labor Fast

Intervention

Drug:
• Isosorbide Mononitrate 40 MG
giving women isosorbide mononitrate 40 MG
• Isosorbide Mononitrate 60 MG
giving women isosorbide mononitrate 60MG
• Misoprostol
Giving women misoprostol

Locations

Country	Name	City	State
Egypt	Algazeerah	Giza

Sponsors (2)

Lead Sponsor	Collaborator
Aljazeera Hospital	Suez Canal University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	the number of women who will be reach active phase within 24 hours	how many women will reach active phase within 24 hours	24 hours